The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: June 2009

Patent Licenses Litigated Lately: Transcore v. ETC and Euclid Chemical v. Vector Corrosion

As a corporate lawyer, I always aim to not wind up facing the pointy end of a deposition. Here are two object lessons courtesy of the U.S. Court of Appeals for the Federal Circuit: TransCore, LP v. Electronic Transaction Consultants Corp. (pdf) TransCore deals with the doctrine of patent exhaustion — that when a customer purchases [...]

Ontario H1N1 Swine Flu Update June 3: Two Deaths, 894 Total Cases

Coverage of Swine Flu has declined, but incidence of Swine Flu has not.  Yesterday, we got the report of a second swine flu-related death in Ontario.  Although the press release goes out of it’s way to emphasize that almost all the cases are considered mild, there is an interesting tidbit here: Six people who have [...]

MRI RFP ISO for Emerging Technology Fun(d)

Ontario’s Ministry of Research and Innovation has put out an RFP for the new $250 million Emerging Technologies Fund. They are looking for someone to evaluate co-investor and investment applications, and to administer and monitor investments for the fund. Here’s the blurb from the RFP Abstract: The OETF is a new $250 million program announced [...]

Women in Math and Technology: Biological Equals

Two stories over the last couple of days, one statistical, one anecdotal, seem worth mentioning as proof of not only how wrong, but how insidiously harmful, Larry Summers’ 2005 comments about women in math were. Let’s start (appropriately enough) with the statistics. A PNAS paper this week by Janet Hyde and Janet Mertz in Madison, [...]

New MaRS Innovation CEO Rafi Hofstein Will Lead Products to the Promised Land

Rafi Hofstein has joined MaRS Innovation as its new CEO.  He was previously the President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem, and since 2005, Chair of Hadasit BioHolding Ltd. (TASE: HBL).  In this role, he oversaw: the commercialization of intellectual property emerging from the Hadassah Medical Organization, [...]

Monday Deal Review: June 1, 2009

Looks like most people were too busy at ASCO to make new deals, but there was a bit of Canadian activity this week. Read on

He Loves Me, He Loves Me Not: CSL Gets Mixed Messages from Uncle Sam

Last week, CSL heard from the Federal Trade Commission that the agency is opposed to CSL’s proposed $3.1 billion merger with Talecris Biotherapeutics. Don’t worry, CSL, Health and Human Services still loves you.  To the tune of a $180 million order for CSL’s H1N1 swine flu vaccine bulk antigen.  HHS will also fund the clinical trials.

Follow

Get every new post delivered to your Inbox.

Join 92 other followers